Company Performance Metrics
Bill Hartman: CEO- Don Swenson: Chief Scientist
The Opportunity is Now: The key to new low cost cancer therapies and $3 billion market. A compact, hospital-practical radiation source only previously possible with nuclear reactors or much more expensive, and larger, accelerator systems. The ILS high-current, low particle-energy, RFI ion linear accelerators (linacs) are the smallest,
lowest-cost-to-own, and to operate, in the world. Strong customer validation in cancer therapies, isotope production, and other markets.
Medical Market Focus and Validation: Selected for $25 million accelerator for isotope production. Key component to make boron neutron capture therapy (BNCT) cost-effective and hospital-practical. Leading BNCT customer would like the RFI to be the “world standard.” Twelve active BNCT customers. $100 million per year market in 10 years. $1 billion per year in 20 years.
